[GM-CSF and G-CSF: cytokines in clinical application]

Area of Science:

• Hematology
• Oncology
• Pharmacology

Context:

• Leukopenia and pancytopenia result from bone marrow dysfunction, impacting patients with diseases like AIDS, cancer, or those undergoing radiation/transplantation.
• Infectious disease morbidity and mortality are significantly increased during neutropenic phases.
• Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and a significant risk of transformation to acute myeloid leukemia (AML).

Purpose:

• To review the clinical use of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and Granulocyte Colony Stimulating Factor (G-CSF) in managing neutropenia.
• To evaluate the efficacy, side effects, and potential risks associated with GM-CSF and G-CSF therapy.
• To discuss the implications of these cytokines in patients with myelodysplastic syndromes.

Summary:

• GM-CSF and G-CSF administration effectively increases neutrophil counts, shortening neutropenia duration and severity.
• Maintenance therapy with these cytokines is well-tolerated, reducing infection frequency and antibiotic treatment duration.
• Side effects are generally mild, though first-dose reactions can occur, particularly with GM-CSF.
• A potential increased risk of acute myeloid leukemia progression exists in myelodysplastic syndrome patients treated with these factors.

Impact:

• GM-CSF and G-CSF offer a promising therapeutic option for managing neutropenia and associated infections.
• Subcutaneous administration is preferred to minimize side effects.
• Careful consideration and limited use are recommended for GM-CSF and G-CSF in myelodysplastic syndrome patients due to leukemogenic risk.